Drug Type Small molecule drug |
Synonyms SN 32976, SN-32976, SN32976 |
Target |
Action inhibitors |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC24H33F2N9O4S |
InChIKeyMKRQBWZUYRPLDM-UHFFFAOYSA-N |
CAS Registry1246202-11-8 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | New Zealand | 17 Jul 2017 | |
| Neoplasms | Preclinical | New Zealand | 17 Jul 2017 |





